Podcasts about Biomarker

In today's episode, we spoke with Tanios S. Bekaii-Saab, MD. Dr Bekaii-Saab is the David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research I, at the Mayo Clinic College of Medicine and Science, the division chair of Hematology/Medical Oncology at Mayo Clinic, and co-leader of the Advanced Clinical and Translational Science Program and the disease group leader for Gastrointestinal Cancers for the Mayo Clinic Comprehensive Cancer Center in Phoenix, Arizona.In our exclusive interview, Dr Bekaii-Saab discussed findings from the final analysis of cohort 3 of the phase 3 BREAKWATER trial (NCT04607421), which were presented at the 2026 ASCO Annual Meeting. These data showed that encorafenib (Braftovi) plus cetuximab (Erbitux) and FOLFIRI (leucovorin, 5-fluorouracil, and irinotecan) significantly improved outcomes compared with standard of care in patients with BRAF V600E–mutant metastatic colorectal cancer (mCRC), building on previously reported data from the trial that led to the February 2026 full FDA approval of encorafenib plus cetuximab and modified FOLFOX6 (leucovorin calcium, fluorouracil, and oxaliplatin) for this patient population. He also highlighted promising bispecific agents targeting VEGF and PD-1, as well as the promise of KRAS G12C inhibitors like calderasib (MK-1084) and sotorasib (Lumakras). Finally, he emphasized that minimal residual disease testing is prognostic and potentially predictive, and can aid in personalized mCRC management.

„Mit zunehmendem Alter verlieren unsere Zellen an Energie. Ein Grund dafür: Beschädigte Mitochondrien werden nicht mehr zuverlässig erkannt und recycelt.“ Genau hier wird Urolithin A interessant: Der Stoff könnte die Mitophagie unterstützen, also den Prozess, mit dem Zellen defekte Mitochondrien abbauen und ihre Energieproduktion stabil halten. Urolithin A steckt jedoch nicht direkt in Granatäpfeln, Walnüssen oder Beeren. Es entsteht erst, wenn bestimmte Darmbakterien deren Pflanzenstoffe umwandeln. Und genau das gelingt nur einem Teil der Menschen. In dieser Deep Dive Folge der artgerecht HEALTH NERDS erklären Podcast Host Felix Moese und Gesundheitswissenschaftler Matthias Baum, wie Urolithin A entsteht, warum das Darmmikrobiom darüber entscheidet und welche Rolle der Stoff für Mitochondrien, Muskelkraft und gesundes Altern spielen könnte. Im Mittelpunkt steht die Frage, ob sich die zelluläre Qualitätskontrolle gezielt unterstützen lässt. Erste Humanstudien zeigen Veränderungen mitochondrialer Biomarker und mögliche Effekte auf Muskelkraft und körperliche Leistungsfähigkeit. Die Datenbasis ist jedoch noch begrenzt. Urolithin A ersetzt weder Bewegung noch Krafttraining. Der Stoff macht vielmehr sichtbar, wie entscheidend es für unsere Gesundheit ist, beschädigte Zellstrukturen rechtzeitig auszusortieren. HEALTH NERDS. Mensch, einfach erklärt. Spare 15% auf Deine erste Bestellung auf https://artgerecht.com mit dem Code: HEALTHNERDS15 (im Warenkorb eingeben) Ein ALL EARS ON YOU Original Podcast.

Alexander Stahmann, Medizinischer Informatiker und Geschäftsführer der MS Forschungs- und Projektentwicklungs-gGmbH, gibt Einblicke in eine wichtige Grundlage der Versorgungsforschung. Er erklärt, wie langfristige Beobachtungen aus neurologischen Praxen, Kliniken und Rehaeinrichtungen ausgewertet werden und warum sie klinische Studien sinnvoll ergänzen. Im Gespräch geht es auch darum, wie die Angaben der Teilnehmenden geschützt werden, welche Rolle Lebensqualität und Alltagseinschränkungen spielen und wie Betroffene künftig stärker selbst eingebunden werden können. Weitere Schwerpunkte sind Therapiepräferenzen, Biomarker, internationale Zusammenarbeit und die langfristige Finanzierung solcher Forschungsstrukturen. Den ausführlichen Beitrag mit zusätzlichen Erklärungen und weiterführenden Links findest du zum Nachlesen auf https://ms-perspektive.de/373-ms-register/ Diese Themen erwarten dich: Unterschiede zwischen klinischen Studien, Abrechnungsinformationen und langfristigen Beobachtungen Erhebung in Praxen, Kliniken und Rehaeinrichtungen Einwilligung, Pseudonymisierung und geregelter Zugang Symptome, Lebensqualität und gesellschaftliche Teilhabe Patient-Reported Outcomes und digitale Selbstdokumentation Wünsche und Prioritäten bei Behandlungsentscheidungen sNfL, GFAP und Forschung zu progredienten Verläufen verständliche Rückmeldung wissenschaftlicher Ergebnisse Zusammenarbeit mit internationalen Forschungsnetzwerken Datenqualität, Weiterentwicklung und nachhaltige Finanzierung Perspektiven für stärker individualisierte Behandlungskonzepte Ressourcenliste Beitrag zu dieser Podcastfolge: MS-Register: Wie Daten Forschung, Therapie und Versorgung verbessern Deutsches MS-Register: Informationen zum Register, zur Teilnahme, zu Projekten und Veröffentlichungen Podcastfolge mit Prof. Dr. Katja Akgün: MS-Biomarker im Verlauf: Was wirklich zählt Podcastfolge zur Arzneimittelsicherheit: Wie Pharmakovigilanz MS-Medikamente sicherer macht MS-PAVED: Pilotstudie zur stärkeren Einbindung der Erfahrungen und Bedürfnisse von Menschen mit MS Grafiken und Auswertungen der DMSG: Aktuelle Darstellungen zu Symptomen, Versorgung und Teilhabe Fazit Registerdaten können nur entstehen, wenn Menschen mit MS bereit sind, ihre Gesundheitsinformationen für Forschung und eine bessere Versorgung zur Verfügung zu stellen. Ebenso wichtig sind die Teams in neurologischen Praxen, Kliniken und Rehaeinrichtungen, die diese Angaben dokumentieren und damit langfristige Auswertungen ermöglichen. Jede Teilnahme kann dazu beitragen, Krankheitsverläufe, Versorgungslücken und die Auswirkungen der MS auf den Alltag besser zu verstehen. --- Bis bald und mach das Beste aus Deinem Leben, Nele Mehr Informationen und positive Gedanken erhältst Du in meinem kostenlosen Newsletter. Hier findest Du eine Übersicht zu allen bisherigen Podcastfolgen.

CardioNerds (Drs. Apoorva Gangavelli, Jenna Skowronski, and Hannah Every) discuss the continuum of prevention and heart failure with Drs. Anu Lala and Martha Gulati. Grounded in a clinical case of a 55-year-old woman with uncontrolled hypertension, type 2 diabetes, and obesity who is on the trajectory toward heart failure, this episode unpacks a paradigm-shifting framework from a joint HFSA/ASPC Scientific Statement. The discussion explores how prevention should not be siloed from heart failure management but rather integrated across a patient’s lifespan—from primary prevention in at-risk individuals, to secondary prevention in those with established heart failure, to tertiary prevention in patients with advanced therapies such as LVADs and heart transplantation. The experts highlight the importance of aggressive risk factor management, biomarker-guided screening, the AHA’s Life’s Essential 8, and the need for multidisciplinary collaboration and systems-level change to shift heart failure care from reactive to proactive. Audio editing for this episode was performed by CardioNerds Intern, Dr. Julia Marques Fernandes. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Prevention PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls Systemic inflammatory diseases are associated with an elevated CVD risk that has significant implications for early detection, risk Heart failure prevention is a continuum, not a checkpoint. Prevention applies at every stage—from at-risk (Stage A) through advanced/post-transplant care—and every clinical encounter is an opportunity to intervene. The AHA’s Life’s Essential 8 (diet, physical activity, nicotine exposure, sleep, BMI, blood lipids, blood glucose, blood pressure) forms the foundation at every stage. Hypertension carries the highest population-attributable risk for heart failure of any modifiable risk factor. In the Framingham Heart Study, 91% of patients with newly diagnosed HF had pre-existing hypertension. The SPRINT trial demonstrated a 38% reduction in HF incidence with intensive blood pressure targets (30 ng/L or NT-proBNP >125 ng/L) identify individuals at heightened risk for progression to symptomatic HF. The ACC/AHA/HFSA guidelines give a Class IIa recommendation for natriuretic peptide screening in at-risk patients. Urine albumin-to-creatinine ratio (UACR) is an underutilized screening tool that provides additional insight into CKM risk. The heart failure label does not close the prevention window—it accentuates it. Secondary prevention through GDMT optimization (quadruple therapy in HFrEF) and continued risk factor management remains critical. Tertiary prevention extends to post-LVAD and post-transplant patients, where hypertension, diabetes, obesity, and CKD management remain essential to long-term outcomes. Show notes For a comprehensive review, please review the full HFSA/ASPC Joint Scientific Statement: Lala A, Beavers C, Blumer V, et al. The Continuum of Prevention and Heart Failure in Cardiovascular Medicine. J Card Fail. 2026;32:75-105. doi:10.1016/j.cardfail.2025.06.013 1. What is the “continuum of prevention” framework, and how does it differ from traditional approaches to heart failure prevention? Historically, prevention and heart failure management have been treated as separate disciplines—primary prevention handled by preventive cardiologists and treatment managed by heart failure specialists. This joint HFSA/ASPC Scientific Statement reframes prevention as a dynamic, continuous process that spans a patient’s entire lifespan, regardless of HF stage or ejection fraction. The framework maps onto the ACC/AHA HF staging system: Primary prevention targets Stage A (“at risk”) and Stage B (“pre-HF”) patients to reduce the burden of incident HF. Secondary prevention targets Stage C (symptomatic) and Stage D (advanced) patients to reduce the impact of established HF through GDMT optimization and ongoing risk factor management. Tertiary prevention encompasses risk factor management in patients with LVADs or heart transplants—populations where hypertension, diabetes, and obesity still drive outcomes. The Central Figure of the statement illustrates that Life’s Essential 8 (blood pressure and lipid control, diabetes management, exercise, sleep, smoking cessation, weight management, and diet/nutrition counseling) forms the foundation at every stage, with pharmacologic and device-based therapies layered on top as disease progresses (Figure) 2. How do traditional risk factors drive heart failure, and what should clinicians prioritize? Hypertension carries the greatest population-attributable risk for HF. In the Framingham Heart Study (N=5,143), HTN was associated with a 2- to 3-fold increased risk of HF, with a population-attributable risk of 39% in men and 59% in women. The SPRINT trial showed a 38% reduction in HF incidence and 25% reduction in the primary composite outcome with intensive BP targets (30 ng/L or NT-proBNP >125 ng/L) are associated with heightened risk for progression to symptomatic HF. In the ARIC study, incorporating NT-proBNP reclassified 20% of older adults without HF into Stage B. Factors that affect interpretation include age, sex, obesity (lower values), and CKD (higher values). High-sensitivity cardiac troponin (hs-cTn): Concentrations above the 99th percentile are now included in the definition of Stage B HF. Troponin testing may complement natriuretic peptides, particularly when BNP/NT-proBNP values are ambiguous. Risk scores: The PCP-HF equation predicts 10-year HF risk using traditional risk factors plus QRS duration. The AHA PREVENT score incorporates HF risk calculation and includes markers of kidney function (albuminuria, eGFR), though it may underestimate risk in men and Black adults. The CKM syndrome staging framework (Stages 0–4) provides a holistic approach to assessing systemic cardiovascular-kidney-metabolic risk. 4. What are the key nontraditional risk factors and cross-cutting themes in heart failure prevention? Genetics: Pathogenic cardiomyopathy variants exist in ~1 in 200 individuals in the general population. The HFSA and ACMG recommend cascade testing to identify at-risk family members. Polygenic risk scores for dilated cardiomyopathy show a 3.8-fold risk for DCM in the top 10th percentile compared with the median. Sex-specific considerations: Women have 2.8 times the odds of developing HFpEF, while men have similarly increased odds of HFrEF. A complete obstetric/gynecologic history is essential—preeclampsia is associated with a 4-fold increased risk of HF. Peripartum cardiomyopathy requires intentional screening in high-risk populations. Cardiotoxic exposures: Clinicians should be aware of medications that cause direct myocardial toxicity (e.g., anthracyclines, trastuzumab, tyrosine kinase inhibitors). A team-based approach with pharmacists can help optimize medication selection and risk factor modification. Social determinants of health: Environmental exposures (air pollution, arsenic, lead, cadmium), food insecurity, financial instability, and limited healthcare access contribute to HF risk and progression. Equity-focused, risk-based prevention strategies are needed. Psychological health: Depression is common in HF and independently associated with worse outcomes. Screening with brief questionnaires (e.g., PHQ-2) is recommended. Meditation, spirituality, and holistic wellness approaches remain underutilized. 5. What systems-level and policy changes are needed to move the needle on heart failure prevention? Multidisciplinary HF prevention clinics that bring together preventive cardiologists, HF specialists, endocrinologists, nephrologists, dietitians, pharmacists, exercise physiologists, and genetic counselors are advocated by the statement. EHR-embedded risk stratification could proactively flag patients on a trajectory toward HF—analogous to sepsis alerts or fall risk flags—enabling earlier intervention, particularly for patients who may not reach a cardiologist. Cardiac rehabilitation remains underutilized, particularly in HFrEF (Class 2b recommendation) and HFpEF (not yet covered by Medicare). The HF-ACTION trial showed quality-of-life benefits, and the REHAB-HF trial showed particular benefit in older patients with HFpEF. Policy priorities include expanding insurance coverage for preventive screening and novel therapies (SGLT2i, GLP-1 RAs, nsMRAs), reducing clinical inertia through team-based care models with closer follow-up intervals, and ensuring equitable access to evidence-based therapies across diverse populations. Digital health and AI hold promise for personalized risk prediction, remote monitoring (e.g., wearable devices, implantable PA pressure monitors), and virtual cardiac rehabilitation to overcome access barriers. Figure  Lala A, Beavers C, Blumer V, et al. The continuum of prevention and heart failure in cardiovascular medicine: a joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology. J Card Fail. 2026;32(1):75-105. doi:10.1016/j.cardfail.2025.06.013) References Key references are bolded. Lala A, Beavers C, Blumer V, et al. The continuum of prevention and heart failure in cardiovascular medicine: a joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology. J Card Fail. 2026;32(1):75-105. doi:10.1016/j.cardfail.2025.06.013 Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063 Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life’s Essential 8: updating and enhancing the American Heart Association’s construct of cardiovascular health: a presidential advisory from the American Heart Association. Circulation. 2022;146(5):e18-e43. doi:10.1161/CIR.0000000000001078 SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-2116. doi:10.1056/NEJMoa1511939 Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557-1562. doi:10.1001/jama.1996.03530440037034 Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997. doi:10.1001/jama.288.23.2981 Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-153. doi:10.1056/NEJM200001203420301 Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720 Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038 Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089-1098. doi:10.1056/NEJMoa2206286 Filippatos G, Anker SD, Agarwal R, et al. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation. 2022;145(6):437-447. doi:10.1161/CIRCULATIONAHA.121.057983 Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475-1485. doi:10.1056/NEJMoa2407107 Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563 Deanfield J, Verma S, Scirica BM, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404(10454):773-786. doi:10.1016/S0140-6736(24)01498-3  Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069-1084. doi:10.1056/NEJMoa2306963 Ndumele CE, Neeland IJ, Tuttle KR, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation. 2023;148(20):1636-1664. doi:10.1161/CIR.0000000000001175 Khan SS, Matsushita K, Sang Y, et al. Development and validation of the American Heart Association’s PREVENT equations. Circulation. 2024;149(6):430-449. doi:10.1161/CIRCULATIONAHA.123.067626 Khan SS, Ning H, Shah SJ, et al. 10-year risk equations for incident heart failure in the general population. J Am Coll Cardiol. 2019;73(19):2388-2397. doi:10.1016/j.jacc.2019.02.057 Bozkurt B, Fonarow GC, Goldberg LR, et al. Cardiac rehabilitation for patients with heart failure: JACC expert panel. J Am Coll Cardiol. 2021;77(11):1454-1469. doi:10.1016/j.jacc.2021.01.030 Packer M. Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity. Circulation. 2018;137(15):1614-1631. doi:10.1161/CIRCULATIONAHA.117.032474 Lala A, Tayal U, Hamo CE, et al. Sex differences in heart failure. J Card Fail. 2022;28(3):477-498. doi:10.1016/j.cardfail.2021.10.006 Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure. Eur J Heart Fail. 2021;23(3):352-380. doi:10.1002/ejhf.2115 Hershberger RE, Givertz MM, Ho CY, et al. Genetic evaluation of cardiomyopathy—a Heart Failure Society of America practice guideline. J Card Fail. 2018;24(5):281-302. doi:10.1016/j.cardfail.2018.03.004 Levine GN, Cohen BE, Commodore-Mensah Y, et al. Psychological health, well-being, and the mind-heart-body connection: a scientific statement from the American Heart Association. Circulation. 2021;143(10):e763-e783. doi:10.1161/CIR.0000000000000947 Ezekowitz JA, Colin-Ramirez E, Ross H, et al. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. Lancet. 2022;399(10333):1391-1400. doi:10.1016/S0140-6736(22)00369-5

Cosmic Latte macht Sommerurlaub. Wir suchen uns die besten Orte im Universum, um unsere Ferien zu verbringen. Den ersten Stop machen wir mit Jana auf dem Planeten K2-18b. Dort gibt es (vielleicht) einen gigantischen Ozean und (noch vielleichter) das eine oder andere Meeresmonster. Unterstützt uns bei [Steady](https://steadyhq.com/de/cosmiclatte/), [Patreon](https://patreon.com/CosmiclattePodcast) oder [Paypal](https://paypal.me/cosmiclattepod).

In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about a blood test that could predict cognitive decline before pathological signs, the use of tirofiban after tenecteplase for stroke, and the role of artificial intelligence in peer review.

"Most people don't understand that the best medicine cabinet is the thing that you put in your body, the food that you eat… So you could eat yourself well as equally as you can eat yourself sick." —Alex Fredericks Voice biomarker technology is turning a 30-second recording into a full-body readiness report — and it's already caught things doctors missed.  In this episode, Justine Reichman sits down with Alex Fredericks, founder and CEO of ToneWell, to unpack how a PEMF frequency technology he encountered as a consultant became a static, auditable database of 150,000 biomarker data points that can flag hydration, hormones, inflammation, and toxins from nothing more than your voice. Alex walks through the real mechanics: a locked algorithm does the analysis, while AI only powers the concierge layer that turns raw output into daily, actionable priorities — a distinction he insists on, because "AI is the workflow, not the analytic."  He shares two striking real-world moments: a client whose 3:30am hormonal spikes were traced to conflicting medications after she recorded a voice snapshot in the moment, and his own nephew, whose oddly low iron reading led to catching a serious kidney infection early. The conversation moves into food, toxins, and gut inflammation, and why Alex refuses to build a diagnostic tool — Tonewell tells you what's going on, not what's wrong, leaving the declaration to practitioners. It's a grounded look at where AI genuinely helps health decisions, and where it should stay firmly in its lane.  Listen to the full conversation for the jiu-jitsu principle — "flow with the go" — that shaped Alex's entire approach to building in a crowded wellness market.  Meet Alex:  Alex Fredericks is the founder and CEO of ToneWell, a voice-based wellness intelligence platform that turns a 30-second voice recording into a ranked, personalized readiness report across energy, sleep, stress, hydration, inflammation, and toxins. Drawing on more than two decades building brands and growth systems in music, consumer goods, and tech, Alex specializes in turning complex bio-data into clear, actionable insights. A self-described Gen X latchkey kid and lifelong problem solver, he approaches AI in wellness with a strict filter: if it doesn't improve decisions and reduce friction, it's entertainment—not innovation. Before Tonewell, Alex worked across the green, organic, and holistic wellness space, helping companies translate emerging technologies into usable products.  Alex is also a Brazilian Jiu Jitsu black belt, and the principle "flow with the go" shapes how he builds resilient systems, sustainable habits, and tools that help people build better relationships with themselves. Website LinkedIn Connect with ToneWell:  Website LinkedIn Instagram Facebook YouTube   Connect with NextGen Purpose: Website Facebook Instagram LinkedIn YouTube Chapters: 01:08 Meet Alex Fredericks: From Growth Engineer to Wellness Founder 05:48 The Voice Resonance Breakthrough Behind Tonewell 07:37 How a 30-Second Voice Scan Collapses Decision Time 10:25 "Flow With the Go": The Jiu Jitsu Rule Behind ToneWell 13:46 Real Case: Catching a 3 A.M. Hormonal Imbalance 19:50 Why Alex Delayed ToneWell's Subscription Model 24:16 Real Case: An Early Kidney Infection Catch 26:36 Inside the AI Concierge's Safety Rails 31:27 What Actually Happens Between Voice and Report 37:43 Why Food Keeps Showing Up in Every Voice Scan 

Wenn ältere Patienten ins Krankenhaus müssen, kommen sie oft als Pflegefälle wieder nach Hause. Doch es gibt Behandlungsleitlinien, die das verhindern können. Plötzlich wie dement: Jeder dritte Mensch über 65 erleidet im Krankenhaus eine akute kognitive Funktionsstörung mit extremen Verwirrtheitszuständen. Das so genannte "Delir" ist eins der Hauptrisiken, wenn Ältere in der Klinik nicht fachgerecht behandelt werden. Denn alte Menschen sind als Patient:innen ähnliche Spezialfälle wie Kinder. Synapsen-Host Korinna Hennig und Medizinjournalistin Daniela Remus haben das beide mit ihren Vätern erlebt. In dieser sehr persönlichen Folge gehen sie der Frage nach, was schieflaufen kann, wenn geriatrische Leitlinien nicht umgesetzt werden. Sie berichten von über 80-jährigen Patienten, die noch zur Quittenernte auf Bäume geklettert sind oder Tischtennis gespielt haben - und nach dem Klinikaufenthalt um ein Haar als Pflegefälle geendet wären. Es geht um kognitive Funktionsreserven, die Suche der Forschung nach einem Biomarker für das Delir-Risiko, Physiotherapie im Klettergurt - und darum, was das Gesundheitssystem sparen kann, wenn Angehörige mit im Krankenzimmer aufgenommen werden.HINTERGRUNDINFORMATIONEN: Delir: Symptome, Definition und Behandlunghttps://www.ndr.de/ratgeber/gesundheit/delir-symptome-definitionund-behandlung,delir-102.htmlStatistische Angaben zur Zahl älterer Patienten im Krankenhaus: https://www.destatis.de/DE/Presse/Pressemitteilungen/2025/11/PD25_398_231.html Betreibbare Betten in deutschen Krankenhäusern: https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Gesundheit/Krankenhauser/Tabellen/gd-krankenhaeuser-jahre.html Überblicksstudie zur Häufigkeit von Delir im Krankenhaus: https://www.sciencedirect.com/science/article/abs/pii/S0163834320301237 S3-Leitlinie Perioperatives Delir bei älteren Patientinnen und Patienten: https://register.awmf.org/de/leitlinien/detail/001-021Überblicks- und Berichtsdaten des RKI zur Häufigkeit von Multimorbidität bei Menschen ab 65 Jahren: https://www.rki.de/DE/Content/GesundAZ/G/Gesundheit-aelterer-menschen/Gesundheit-aelterer-menschen_node.htmlCornell-Preprint von 2024 zu Delirraten auf Intensivstationen: https://arxiv.org/abs/2410.17363 PAWEL-Studie: Delirprävention durch ein Multikomponentenprogramm bei älteren chirurgischen Patientinnen und Patienten: https://www.umg.eu/forschung/klinische-studien/projekt-pawel/Schätzungen zur Mangelernährung bei Krankenhausaufnahme: https://www.aerzteblatt.de/news/mangelernaehrung-im-krankenhaus-etwa-55000-vermeidbare-todesfaelle-a2ea8292-8741-40b1-918a-db51a3be287f Alle weiteren Quellen findet ihr im Artikel zur Folge auf der Synapsenseite:https://www.ndr.de/nachrichten/podcastsynapsen100.htmlHabt ihr Feedback oder einen Lifehack aus der Welt der Wissenschaft? Schreibt uns an synapsen@ndr.deHier geht's zu ARD Gesund: https://www.ndr.de/ratgeber/gesundheit

Wenn ältere Patienten ins Krankenhaus müssen, kommen sie oft als Pflegefälle wieder nach Hause. Doch es gibt Behandlungsleitlinien, die das verhindern können. Plötzlich wie dement: Jeder dritte Mensch über 65 erleidet im Krankenhaus eine akute kognitive Funktionsstörung mit extremen Verwirrtheitszuständen. Das so genannte "Delir" ist eins der Hauptrisiken, wenn Ältere in der Klinik nicht fachgerecht behandelt werden. Denn alte Menschen sind als Patient:innen ähnliche Spezialfälle wie Kinder. Synapsen-Host Korinna Hennig und Medizinjournalistin Daniela Remus haben das beide mit ihren Vätern erlebt. In dieser sehr persönlichen Folge gehen sie der Frage nach, was schieflaufen kann, wenn geriatrische Leitlinien nicht umgesetzt werden. Sie berichten von über 80-jährigen Patienten, die noch zur Quittenernte auf Bäume geklettert sind oder Tischtennis gespielt haben - und nach dem Klinikaufenthalt um ein Haar als Pflegefälle geendet wären. Es geht um kognitive Funktionsreserven, die Suche der Forschung nach einem Biomarker für das Delir-Risiko, Physiotherapie im Klettergurt - und darum, was das Gesundheitssystem sparen kann, wenn Angehörige mit im Krankenzimmer aufgenommen werden.HINTERGRUNDINFORMATIONEN: Delir: Symptome, Definition und Behandlunghttps://www.ndr.de/ratgeber/gesundheit/delir-symptome-definitionund-behandlung,delir-102.htmlStatistische Angaben zur Zahl älterer Patienten im Krankenhaus: https://www.destatis.de/DE/Presse/Pressemitteilungen/2025/11/PD25_398_231.html Betreibbare Betten in deutschen Krankenhäusern: https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Gesundheit/Krankenhauser/Tabellen/gd-krankenhaeuser-jahre.html Überblicksstudie zur Häufigkeit von Delir im Krankenhaus: https://www.sciencedirect.com/science/article/abs/pii/S0163834320301237 S3-Leitlinie Perioperatives Delir bei älteren Patientinnen und Patienten: https://register.awmf.org/de/leitlinien/detail/001-021Überblicks- und Berichtsdaten des RKI zur Häufigkeit von Multimorbidität bei Menschen ab 65 Jahren: https://www.rki.de/DE/Content/GesundAZ/G/Gesundheit-aelterer-menschen/Gesundheit-aelterer-menschen_node.htmlCornell-Preprint von 2024 zu Delirraten auf Intensivstationen: https://arxiv.org/abs/2410.17363 PAWEL-Studie: Delirprävention durch ein Multikomponentenprogramm bei älteren chirurgischen Patientinnen und Patienten: https://www.umg.eu/forschung/klinische-studien/projekt-pawel/Schätzungen zur Mangelernährung bei Krankenhausaufnahme: https://www.aerzteblatt.de/news/mangelernaehrung-im-krankenhaus-etwa-55000-vermeidbare-todesfaelle-a2ea8292-8741-40b1-918a-db51a3be287f Alle weiteren Quellen findet ihr im Artikel zur Folge auf der Synapsenseite:https://www.ndr.de/nachrichten/podcastsynapsen100.htmlHabt ihr Feedback oder einen Lifehack aus der Welt der Wissenschaft? Schreibt uns an synapsen@ndr.deHier geht's zu ARD Gesund: https://www.ndr.de/ratgeber/gesundheit

Die Biomarkerdiagnostik in der Onkologie wird zunehmend komplexer, aber auch immer wichtiger für individualisierte Therapieentscheidungen. Im Dezember 2025 wurde vom Leitlinienprogramm Onkologie die aktualisierte deutsche S3-Leitlinie Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms vorgelegt. Unter anderem wurden die Empfehlungen für Diagnostik und Screening überarbeitet. Welche Auswirkungen dies auf den Praxisalltag sowohl von Pathologie als auch Klinik hat, hören Sie im Podcast.

Are you effectively linking cognitive tools with biomarkers for accurate Alzheimer's disease (AD) diagnosis? Credit available for this activity expires: 06/25/2027 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/case-based-discussion-linking-cognitive-testing-biomarker-2026a1000law?ecd=bdc_podcast_libsyn_mscpedu

Highlights from the PER® CME activity "Live Tumor Board: Translating Biomarker Insights and Therapeutic Advances Into Endometrial Cancer Practice" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Kathleen N. Moore, MD, MS, FASCO; Ritu Salani, MD, MBA; Casey Cosgrove, MD; and Ebony R. Hoskins, MD, FACOG, discuss several cases of endometrial cancer using biomarkers to drive treatment decisions.Earn CME credit by completing the full accredited activity (available through June 26, 2027):https://www.gotoper.com/iog26endometrial-activityThis podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from BioNTech; Eisai, Inc.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Most health issues don't appear overnight. Long before a diagnosis is made, the body often provides subtle clues that something needs closer attention. On this episode of The Dr. Hyman Show, I talk with double board-certified fertility physician Dr. Natalie Crawford about her new book, The Fertility Formula, and why fertility and hormone health can reveal far more about your health than many people realize. We discuss: Why the menstrual cycle may be one of the clearest indicators of overall health How sleep, stress, and insulin resistance may be affecting your hormones The overlooked symptoms that may signal deeper dysfunction What many women get wrong about PCOS and hormone health Practical strategies to support fertility, reduce inflammation, and improve long-term health Health challenges don't begin when symptoms become impossible to ignore. They often start years earlier. Being able to recognize those signals is one of the most effective ways to take a proactive approach to your health. Looking for a place to start? My 10-Day Detox is designed to help reduce inflammation, reset your metabolism, and build a stronger foundation for long-term health. View Show Notes From This Episode Sign up for Dr. Hyman's Brainshaping Academy to learn how to nourish the biological systems that support your mental, emotional, and cognitive health - https://drhyman.com/products/brainshaping?utm_source=dr_hyman_show&utm_medium=newsletter&utm_campaign=may_27&utm_content=link Get Free Weekly Health Tips from Dr. Hyman https://drhyman.com/pages/picks?utm_campaign=shownotes&utm_medium=banner&utm_source=podcast Sign Up for Dr. Hyman's Weekly Longevity Journal https://drhyman.com/pages/longevity?utm_campaign=shownotes&utm_medium=banner&utm_source=podcast Join the 10-Day Detox to Reset Your Health https://drhyman.com/pages/10-day-detox Join the Hyman Hive for Expert Support and Real Results https://drhyman.com/pages/hyman-hive This episode is brought to you by BIOptimizers, Paleovalley, Perfect Amino, Rho, Sunlighten, and Pique. Head to bioptimizers.com/hyman and use promo code HYMAN at checkout to save 15%. Head to paleovalley.com/hyman to save 15% off your first order today. Go to bodyhealth.com and use code HYMAN20 to get 20% off your first order. Head over to rhonutrition.com and use code HYMAN to get 20% off their entire product line. Visit sunlighten.com and use code HYMAN to save up to $1600 today. Secure 20% off your order plus a free starter kit at piquelife.com/hyman (0:00) Infertility and fertility as indicators of overall health (3:10) Welcome Natalie Crawford and reframing fertility as health optimization (5:21) Access to fertility data, proactive health, and reproductive well-being (7:25) Menstrual cycle, hormonal communication, and ovulatory dysfunction (14:39) Inflammation's role in reproductive health (19:11) Reproductive health relevance beyond fertility and early warning signs (21:13) Medical training, coping mechanisms, and personal journey with celiac disease (23:48) Self-advocacy and higher infertility rates among female physicians (25:03) Personal experience with recurrent pregnancy loss (27:09) Inflammation, genetics, family history, and patient-centric care (35:38) Reducing inflammation, mitochondrial health, and top health recommendations (38:28) Sleep, stress, and their effects on fertility (47:25) Insulin resistance, diet optimization, and fertility (55:37) Environmental toxins, plastics, and hormone health (1:00:09) Unscented vs. fragrance-free products and toxin reduction (1:01:18) Fertility, aging, ovarian health, and AMH testing (1:07:38) Male fertility, sperm health, and testosterone (1:09:10) Resources for reproductive health and personalized care (1:10:16) Outro and sponsor acknowledgment

«Statt Gewebe zu entnehmen, reicht bei der sogenannten Liquid Biopsy eine einfache Blutentnahme», erklärt Heather Dawson vom Institut für Gewebemedizin und Pathologie der Universität Bern. Diese Flüssigbiopsie gilt als einer der spannendsten Ansätze der modernen Krebsmedizin. Doch wie gross ist ihr Potenzial und wo liegen die Grenzen? Gemeinsam mit Sabine Schmid vom Inselspital Bern ordnet Dawson den aktuellen Stand ein. Beide Expertinnen betonen, dass die Methode für viele Anwendungen noch nicht ausreichend erforscht ist und weiterhin kritisch untersucht werden muss. Im Zentrum der Folge steht Dawsons Forschung zu Darmkrebs: Flüssigbiopsien könnten künftig helfen, Therapien gezielter auf einzelne Patientinnen und Patienten abzustimmen, unnötige Untersuchungen und Behandlungen zu vermeiden und neue Wege für die Früherkennung zu eröffnen. Sicher ist: Liquid Biopsy wird noch einen grossen Einfluss auf die Krebsmedizin haben.

June 23, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: Temple unveils Entropy, a new biomarker measuring real-time metabolic and stress load using blood flow patterns at the temple to track the physiological cost of exercise and recovery Amazfit launches Helio Strap Pro adding motion tracking and muscular load data for HYROX competitors, building a purpose-built system for hybrid training  Neko Health adds body composition tracking and wearable integrations, combining a year of sleep and activity data with in-clinic scans measuring visceral fat and metabolic health More from Fitt: Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital. Subscribe to our newsletter → insider.fitt.co/subscribe Work with our recruiting firm → https://talent.fitt.co/ Follow us on Instagram → https://www.instagram.com/fittinsider/ Follow us on LinkedIn → linkedin.com/company/fittinsider Reach out → insider@fitt.co

Do you know how tumor-agnostic therapies are helping to reshape cancer treatment pathways? Credit available for this activity expires: 6/16/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/shaping-future-precision-oncology-biomarker-driven-care-2026a1000jpk?ecd=bdc_podcast_libsyn_mscpedu

Please visit answersincme.com/CNW860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Stephen V. Liu, MD and Amber Fake. In this activity, an expert in non–small-cell lung cancer (NSCLC) discusses the evolving patient-centered management of HER2-mutant NSCLC, focusing on the use of HER2-targeted TKIs. Upon completion of this activity, participants should be better able to: Describe how HER2-targeted TKIs may address the clinical needs for diverse patient populations with HER2-mutant NSCLC; Implement evidence-based molecular profiling to identify HER2 alterations in NSCLC; Evaluate the clinical evidence of current and emerging HER2-targeted treatments; and Integrate shared decision-making strategies to align preferences for patients with HER2-mutant NSCLC.

Please visit answersincme.com/CNW860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Stephen V. Liu, MD and Amber Fake. In this activity, an expert in non–small-cell lung cancer (NSCLC) discusses the evolving patient-centered management of HER2-mutant NSCLC, focusing on the use of HER2-targeted TKIs. Upon completion of this activity, participants should be better able to: Describe how HER2-targeted TKIs may address the clinical needs for diverse patient populations with HER2-mutant NSCLC; Implement evidence-based molecular profiling to identify HER2 alterations in NSCLC; Evaluate the clinical evidence of current and emerging HER2-targeted treatments; and Integrate shared decision-making strategies to align preferences for patients with HER2-mutant NSCLC.

Warum ist die Diagnose von postinfektiösen Erkrankungen bei Kindern so schwierig? Eine Sonderfolge mit Dr. Daniel Vilser.Es ist schwer zu sagen, wie viele Kinder und Jugendliche in Deutschland an postinfektiösen Erkrankungen leiden - ausgelöst durch verschiedene Erreger, nicht nur durch Corona. Schätzungen reichen von 10.000 bis 100.000 Fällen. Das Krankheitsbild ist divers, deshalb sind Diagnose und Therapie nach wie vor schwierig. Obwohl es für Kinder neuerdings ein bundesweites Versorgungsnetzwerk gibt, klagen betroffene Familien weiter über Wartezeiten und Unkenntnis im Gesundheitssystem, und es mangelt an großen Studien. Was weiß man mittlerweile über die Krankheitsmechanismen? Darüber spricht "Synapsen"-Host Korinna Hennig in dieser Sonderfolge mit Dr. Daniel Vilser, der sich während der Pandemie als einer der ersten mit Long Covid bei Kindern beschäftigt hat. Heute ist er Chefarzt der Klinik für Kinder- und Jugendmedizin am AMEOS-Klinikum in Neuburg und leitet dort eine Ambulanz für Betroffene. Er schildert die vergebliche Suche nach einem Biomarker und den langen Weg zur Evidenz bei Medikamenten - und erzählt, warum er seinen Patientinnen und Patienten trotz allem Hoffnung machen will.HINTERGRUNDINFORMATIONENVersorgungsnetz für Postinfektiöse Erkrankungen bei Kindern in Deutschland: https://pednet-lc.de/Daten aus der RECOVER-Studie zu Long Covid bei Kindern und Jugendlichen: https://jamanetwork.com/journals/jama/fullarticle/2822770Studie von Daniel Vilser et al. zu Long Covid-Subtypen: https://www.nature.com/articles/s41467-026-72224-yStudie zu Risikofaktoren für schweres Post Covid bei jungen Patient:innen: https://link.springer.com/article/10.1007/s00431-026-06995-3Alle weiteren Quellen findet ihr im Artikel zur Folge auf der Synapsenseite:https://www.ndr.de/nachrichten/podcastsynapsen100.htmlHabt ihr Feedback oder einen Lifehack aus der Welt der Wissenschaft? Schreibt uns an synapsen@ndr.deHier geht's zu ARD Gesund:https://www.ndr.de/ratgeber/gesundheit

Warum ist die Diagnose von postinfektiösen Erkrankungen bei Kindern so schwierig? Eine Sonderfolge mit Dr. Daniel Vilser.Es ist schwer zu sagen, wie viele Kinder und Jugendliche in Deutschland an postinfektiösen Erkrankungen leiden - ausgelöst durch verschiedene Erreger, nicht nur durch Corona. Schätzungen reichen von 10.000 bis 100.000 Fällen. Das Krankheitsbild ist divers, deshalb sind Diagnose und Therapie nach wie vor schwierig. Obwohl es für Kinder neuerdings ein bundesweites Versorgungsnetzwerk gibt, klagen betroffene Familien weiter über Wartezeiten und Unkenntnis im Gesundheitssystem, und es mangelt an großen Studien. Was weiß man mittlerweile über die Krankheitsmechanismen? Darüber spricht "Synapsen"-Host Korinna Hennig in dieser Sonderfolge mit Dr. Daniel Vilser, der sich während der Pandemie als einer der ersten mit Long Covid bei Kindern beschäftigt hat. Heute ist er Chefarzt der Klinik für Kinder- und Jugendmedizin am AMEOS-Klinikum in Neuburg und leitet dort eine Ambulanz für Betroffene. Er schildert die vergebliche Suche nach einem Biomarker und den langen Weg zur Evidenz bei Medikamenten - und erzählt, warum er seinen Patientinnen und Patienten trotz allem Hoffnung machen will.HINTERGRUNDINFORMATIONENVersorgungsnetz für Postinfektiöse Erkrankungen bei Kindern in Deutschland: https://pednet-lc.de/Daten aus der RECOVER-Studie zu Long Covid bei Kindern und Jugendlichen: https://jamanetwork.com/journals/jama/fullarticle/2822770Studie von Daniel Vilser et al. zu Long Covid-Subtypen: https://www.nature.com/articles/s41467-026-72224-yStudie zu Risikofaktoren für schweres Post Covid bei jungen Patient:innen: https://link.springer.com/article/10.1007/s00431-026-06995-3Alle weiteren Quellen findet ihr im Artikel zur Folge auf der Synapsenseite:https://www.ndr.de/nachrichten/podcastsynapsen100.htmlHabt ihr Feedback oder einen Lifehack aus der Welt der Wissenschaft? Schreibt uns an synapsen@ndr.deHier geht's zu ARD Gesund:https://www.ndr.de/ratgeber/gesundheit

Professor Mark Kendall, Founder and CEO of WearOptimo, is a pioneer in micro-wearable technology and highlights the limitations of current wearables that capture only basic signals.  The WearOptimo platform uses a skin patch with painless microelectrodes to measure a range of biomarkers in the interstitial fluid just beneath the skin surface.  The company's first product is a continuous hydration monitor designed to address the widespread and under-recognized health problems caused by dehydration due to lifestyle, disease, and working conditions. Mark explains, "We are all familiar with wearables. They're everywhere these days. And when we think about wearables, we're thinking about really basic signals, like an Apple Watch, an Oura ring, or a Whoop. And they're useful for really basic things. But the challenge is that there are all manner of really important health signals out there that today's wearables, like those, are just unable to reach. So, what we're looking to tackle with our technology, our powerful platform, the micro-wearable platform, is gaining access to those key signals that today's wearables are unable to reach and really opening up genuine healthcare."   "It feels just like a sticker, as I said, but the important piece is something that's microscopic. It's microelectrodes. It's an embodiment of a field called microneedles, and I'm a founder of that field. And those microelectrodes just pierce this tough outer dead layer of skin, called the stratum corneum, and reach this location just below the skin's surface. And in that location is a rich reservoir of signals. And we measure those with bio-impedance sweeps. We pull out electrical signals from the body, and use our bespoke, novel AI model to read those signals and give us distinct health outcomes." #WearOptimo #MicroWearable #WearableTech #HealthMonitoring #HydrationHealth # #MedTech #MicroneedleTechnology #PrecisionHealth #HealthcareInnovation #DigitalHealth #Wearables #Microneedles #HydrationMonitoring #Biomarkers #PatientSafety #PerioperativeCare #OccupationalHealth #MilitaryMedicine #AIinHealthcare #EdgeComputing #PreventiveCare wearoptimo.com Download the transcript here

Professor Mark Kendall, Founder and CEO of WearOptimo, is a pioneer in micro-wearable technology and highlights the limitations of current wearables that capture only basic signals.  The WearOptimo platform uses a skin patch with painless microelectrodes to measure a range of biomarkers in the interstitial fluid just beneath the skin surface.  The company's first product is a continuous hydration monitor designed to address the widespread and under-recognized health problems caused by dehydration due to lifestyle, disease, and working conditions. Mark explains, "We are all familiar with wearables. They're everywhere these days. And when we think about wearables, we're thinking about really basic signals, like an Apple Watch, an Oura ring, or a Whoop. And they're useful for really basic things. But the challenge is that there are all manner of really important health signals out there that today's wearables, like those, are just unable to reach. So, what we're looking to tackle with our technology, our powerful platform, the micro-wearable platform, is gaining access to those key signals that today's wearables are unable to reach and really opening up genuine healthcare."   "It feels just like a sticker, as I said, but the important piece is something that's microscopic. It's microelectrodes. It's an embodiment of a field called microneedles, and I'm a founder of that field. And those microelectrodes just pierce this tough outer dead layer of skin, called the stratum corneum, and reach this location just below the skin's surface. And in that location is a rich reservoir of signals. And we measure those with bio-impedance sweeps. We pull out electrical signals from the body, and use our bespoke, novel AI model to read those signals and give us distinct health outcomes." #WearOptimo #MicroWearable #WearableTech #HealthMonitoring #HydrationHealth # #MedTech #MicroneedleTechnology #PrecisionHealth #HealthcareInnovation #DigitalHealth #Wearables #Microneedles #HydrationMonitoring #Biomarkers #PatientSafety #PerioperativeCare #OccupationalHealth #MilitaryMedicine #AIinHealthcare #EdgeComputing #PreventiveCare wearoptimo.com Listen to the podcast here

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this Mind Moments episode, Scott Grossman, MD, assistant professor of neurology and ophthalmology at NYU Grossman School of Medicine, discusses emerging research on inter-eye retinal nerve fiber layer (RNFL) asymmetry as a biomarker of prior optic neuritis in pediatric-onset multiple sclerosis (POMS). Drawing from data presented at the 2026 American Academy of Neurology Annual Meeting, Grossman explains how optical coherence tomography (OCT) may help improve diagnostic confidence in pediatric MS by identifying remote optic nerve injury, while also outlining how a 4-micron inter-eye RNFL difference emerged as the optimal threshold in this cohort. The conversation also explores the role of OCT within the updated 2024 McDonald Criteria, the feasibility of integrating OCT into routine neurology practice, challenges surrounding normative pediatric OCT data, and future research directions involving visible light OCT and broader population datasets. Looking for more Multiple Sclerosis discussion? Check out the NeurologyLive® Multiple Sclerosis clinical focus page.Episode Breakdown: 1:15 – Optic nerve involvement and updated MS diagnostic criteria  3:20 – Pediatric RNFL asymmetry thresholds and interpretation of study findings 5:15 – Clinical implications of OCT biomarkers in pediatric-onset MS  6:40 – Neurology News Network  8:40 – Feasibility of incorporating OCT into neurology and MS practice  10:15 – Future research directions, including normative data and visible light OCT The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Approves AXS-05 as New Treatment for Alzheimer Disease Agitation FDA Approves Ocrelizumab for Pediatric Patients With Relapsing-Remitting Multiple Sclerosis Efgartigimod Gains FDA Approval as First Treatment for Seronegative Forms of Myasthenia Gravis Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Pranav Garimella joins host Catherine Glass to explore why early detection of chronic kidney disease remains challenging. From high-risk populations to emerging plasma and urine biomarkers, this episode examines how earlier diagnosis and improved risk stratification can transform patient outcomes. Timestamps: 00:59 – Challenges of early detection 05:12 – Populations for intensive screening 09:08 – Plasma and urine biomarkers 13:45 – Biomarker-driven risk stratification

Welcome to OncLive On Air®! I'm your host today, Courtney Flaherty.OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In today's episode, Michael J. Pishvaian, MD, PhD, sat down to discuss the evolving role of biomarker-directed strategies in gastrointestinal (GI) oncology, as well as the importance of early comprehensive testing to identify molecular drivers and resistance mechanisms when approaching frontline treatment selection and sequencing. Pishvaian serves as director of the Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs for the Johns Hopkins Kimmel Cancer Center in the National Capital Region.Pishvaian began the discussion by highlighting the shift from a disease-site-specific approach to a molecularly defined paradigm, noting that microsatellite instability–high status and NTRK fusions now dictate therapy regardless of tumor origin. He reviewed the transformational data from the phase 3 HERIZON-GE-01 trial (NCT04276493), positing that zanidatamab (Ziihera) could become the new standard of care for HER2-positive upper GI cancers due to unprecedented survival outcomes. He also emphasized the emergence of Claudin 18.2-directed therapies, noting that data from the phase 2 ILUSTRO study (NCT03505320) demonstrates remarkable progression-free survival when adding zolbetuximab (Vyloy) to mFOLFOX6 and nivolumab (Opdivo) for high-expressing subgroups.The conversation then shifted to colorectal cancer, where Dr. Pishvaian detailed how data from the phase 3 BREAKWATER trial (NCT03845036) has "locked in" a paradigm requiring frontline testing for BRAF V600E mutations to guide the use of encorafenib (Braftovi) plus cetuximab (Erbitux). He also discussed the "care revolution" in KRAS inhibition, spotlighting the significant survival benefits seen with daraxonrasib in pancreatic cancer and the potential for novel allele-specific inhibitors to combat disease resistance.Finally, Pishvaian addressed the practicalities of implementation, noting that testing rates in the community remain low. He advocated for prioritizing testing, including liquid biopsies and ctDNA, at the time of initial diagnosis to ensure no patient is left behind.This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive.

Could neoadjuvant immunotherapy be considered part of the standard of care for patients with mismatch repair deficient (dMMR) colon cancer? Credit available for this activity expires: 5/1/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/practical-community-colorectal-cancer-clinic-aligning-2026a1000dw7?ecd=bdc_podcast_libsyn_mscpedu

In this episode, Dr. Rena Malik welcomes Dr. Rachel Rubin to explore the often-overlooked aspects of women's sexual health, including clitoral anatomy, clitoral adhesions, and the impact of hormones throughout the lifespan. The conversation covers essential topics such as sexual pain, the role of hormones during menopause, and why devices and open communication are vital for pleasurable sex. Listeners will come away with practical insights into understanding their own bodies, advocating for better healthcare, and normalizing conversations around sexual well-being. Want clean plant-based skincare: Use code RENA for 20% off at https://www.basedbodyworks.comSave 20% Off Honeylove by going to http://honeylove.com/RENA #honeylovepod Become a Member to Receive Exclusive Content: renamalik.supercast.com Schedule an appointment with me: https://www.renamalikmd.com/appointments ▶️Chapters: 00:00:00 Introduction00:02:31 Why Couples Need Better Sexual Health Care00:05:29 The Clitoris and the Anatomy Most Doctors Never Learn00:06:56 Clitoral Adhesions, Pleasure, and Painful Missed Diagnoses00:12:33 How Menopause Changes the Labia and Genital Tissue00:22:32 Sex Education, Masturbation, Shame, and Communication00:29:30 Vaginal Hormones, Menopause, and Painful Sex00:43:16 The Vulvar Vestibule and Hidden Causes of Sexual Pain00:48:28 Birth Control, Hormones, and Sexual Function01:25:08 Sexual Health as a Biomarker of Overall Health01:28:41 Final Takeaways and Closing Reflections Stay connected with Dr. Rachel Rubin on social media for daily insights and updates. Don't miss out—follow her now and check out these links! INSTAGRAM - https://www.instagram.com/drrachelrubin/?hl=en FACEBOOK - https://web.facebook.com/DrRachelRubin/?_rdc=1&_rdr# YOUTUBE - https://www.youtube.com/@DrRachelRubin X - https://x.com/drrachelrubin WEBSITE - https://www.rachelrubinmd.com/ Let's Connect!: WEBSITE: http://www.renamalikmd.com YOUTUBE: https://www.youtube.com/@RenaMalikMD INSTAGRAM: http://www.instagram.com/RenaMalikMD TWITTER: http://twitter.com/RenaMalikMD FACEBOOK: https://www.facebook.com/RenaMalikMD/ LINKEDIN: https://www.linkedin.com/in/renadmalik PINTEREST: https://www.pinterest.com/renamalikmd/ TIKTOK: https://www.tiktok.com/RenaMalikMD ------------------------------------------------------ DISCLAIMER: This podcast is purely educational and does not constitute medical advice. The content of this podcast is my personal opinion, and not that of my employer(s). Use of this information is at your own risk. Rena Malik, M.D. will not assume any liability for any direct or indirect losses or damages that may result from the use of information contained in this podcast including but not limited to economic loss, injury, illness or death. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Alzheimer's Association released a Special Report that updates dementia and dementia care information. I have on;y read about 1/3 of the info so far, so I expect I'll have a lot more to share over the nexrt several weeks. The industry is getting better at discovering, diagnosing, and managing dementia. I tried to get a link to the report, but I can't find it. The title is "2026 Alzheimer's Disease Facts and Figures". There is a ton of info at the Alzheimer's Association website website https://www.alz.org/ Check out the "About" and 'Research" tabs, and then schedule with me to protect your family, assets and choices when extended care is needed at home, in a family member's home or in a facility/community setting Schedule here

In 1969, Harvard pathologist Kilmer McCully discovered elevated homocysteine causes arterial damage and heart disease. He was forced out of Harvard. The Framingham Heart Study confirmed him. Then the AHA buried it anyway.CHAPTERS:00:00 - McCully discovery and suppression01:20 - Part 1: What homocysteine does to arteries (6 mechanisms)03:25 - Part 2: The evidence they ignored03:40 - Every 5 umol/L: 20-30% higher CAD risk, 60% stroke risk04:50 - Alzheimers risk +48% (meta-analysis, 7,474 subjects)06:10 - Part 3: Why it was abandoned (VISP, NORVIT, HOPE-2)07:50 - Cochrane: B vitamins reduced stroke 10%08:20 - CSPPT: folic acid reduced stroke 21% to 73%09:10 - Part 4: Your brain on homocysteine09:25 - VITACOG: brain atrophy 30% slower, 53% in high-Hcy group10:05 - PNAS 2013: 7x less hippocampal atrophy11:00 - Part 5: What to do11:10 - Test fasting homocysteine: target under 8-10 umol11:40 - Methylfolate, methylcobalamin, P5PREFERENCES:Homocysteine CVD Risk 2025: PMC12564181VITACOG Trial (PLoS ONE, 2010): PMC2935890VITACOG 2025 Metabolomics: PubMed 40684250Homocysteine Alzheimers Risk: PMC12280720Cochrane B Vitamins Stroke: CochraneCSPPT Folic Acid: ACCJAMA 2010 Meta-Analysis: JAMAHOST: Dr. Robert Lufkin MD | robertlufkinmd.com⭐ Enjoying the show? Please leave a 5-star review on Apple Podcasts — it takes 30 seconds and helps more people discover the science of health and longevity. Thank you!New episodes every Tuesday & Thursday. Subscribe so you don't miss one.Continue this conversation on Substack: https://robertlufkinmd.substack.comLies I Taught In Medical School — Free sample chapter: https://www.robertlufkinmd.com/lies/Web: https://www.robertlufkinmd.comYouTube: https://www.youtube.com/robertlufkinmdX: https://x.com/robertlufkinmdInstagram: https://www.instagram.com/robertlufkinmd/TikTok: https://www.tiktok.com/@robertlufkinLinkedIn: https://www.linkedin.com/in/robertlufkinmd/

Are you ready to stop guessing about your health and start getting answers? In this episode, Dana Irvine, FDNP, sits down with Kristy Berry, CEO of Cenegenics, to unpack what performance aging actually looks like for women — and why the conventional healthcare model is failing us. Together, they dig into the power of comprehensive biomarker testing, personalized health protocols, and the functional, root-cause approach to navigating menopause, hormone imbalance, and long-term vitality.Kristy shares how Cenegenics uses over 270 blood biomarkers alongside cognitive and physical assessments to build truly individualized health strategies — moving far beyond the one-size-fits-all advice most women have been handed for decades. You'll hear why continuous monitoring matters, how lifestyle factors like sleep, nutrition, and stress are non-negotiable foundations, and why hormones and peptides — while powerful tools — should support a solid wellness framework, not replace one.If you've ever felt dismissed by your doctor, confused by conflicting hormone health advice, or simply ready to take a proactive, empowered approach to aging well, this episode is your roadmap.Kristy Berry is the CEO of Cenegenics, the world's largest and most experienced performance health and age management medicine practice, with 20 U.S. locations and 8 international centers. Since joining the executive team in 2021, Kristy has led the transformation of Cenegenics from a disease-treatment model to a proactive, preventive approach that helps individuals achieve peak cognitive and physical health at every stage of life. With a background in nursing and healthcare management, Kristy is a passionate advocate for personalized medicine, comprehensive biomarker testing, and empowering women to take full ownership of their health journey.

Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics: Role of PD-L1 status, tumor histology and pulmonary disease in selection of immune checkpoint inhibition as up-front therapy (0:00) Impact of metastatic site and autoimmune disease on clinical decision-making in the use of immune checkpoint inhibition (5:56) Biomarker assessment approach and treatment selection (10:50) CME information and select publications

In dieser Folge spreche ich mit Robin Sorg (Aware Health) darüber, wie präventive Bluttests und Biomarker dir helfen können, Training, Regeneration und Gesundheit besser zu verstehen – ohne Biohacking-Hype, dafür mit konkreter Praxis: testen – handeln – testen.Wir klären u. a.:Warum Normbereich nicht automatisch optimal (für Sport) bedeutetWeshalb ein einzelner Wert selten reicht (Beispiel Ferritin + Entzündungsmarker)Warum „mehr Supplements“ nicht immer besser ist – besonders bei Vitamin DWieso der Omega-3-Index für Ausdauersportler unterschätzt istWie oft Testen sinnvoll ist (Daumenregeln für ambitionierte Sportler vs. Freizeit)Was passiert, wenn Werte stark auffällig sind (Einordnung, nächste Schritte)Wie Aware Blutdiagnostik alltagstauglich macht – inkl. Standorten und dm-PilotLinks & Infos (WERBUNG):Aware Health: www.aware.app/deSport-Paket / passende Pakete: www.aware.app/de/sport-bluttestStandorte: www.aware.app/de/standorteHinweis: Die Inhalte dienen der Information und ersetzen keine ärztliche Beratung oder Diagnose. Bei Beschwerden oder Unsicherheit bitte medizinisch abklären lassen.*WerbesendungAlle aktuellen Partner findest du hier:NordVPN mit verschlüsselter Verbindung und blockiert schädliche Seiten & Tracker.Exklusiv: Großer Rabatt auf das 2-Jahrespaket + 4 Extra-Monate gratis.

Dr. Michel G. Khouri reviews a landmark study examining patients with AL amyloidosis who achieved a complete cardiac biomarker response, highlighting profound improvements in cardiac structure, function, and long-term survival that rival the general population. The discussion underscores the transformative impact of early diagnosis and modern plasma cell–directed therapies, while reminding clinicians that ongoing multidisciplinary cardiac care remains essential even after sustained cardiac remission.

Galectin-3, perhaps a word you have never heard of, is a biomarker that plays a powerful role in inflammation, immune function, cancer progression, and even treatment response.  But shining a light on the "often overlooked" tools is why you are here, and why we interviewed Ruby Tischoff, a Functional Diagnostic Nutrition Practitioner with 25 years of experience in integrative medicine and nutraceutical science. Tune in to uncover valuable insights into targeting testing and how lifestyle factors (toxic exposures, chronic stress, etc.) can elevate galectin-3. And since we are women of solutions, of course, we included steps that may help bring your levels back into balance. One of the main ones Ruby suggests (and so do we!) is Modified Citrus Pectin. Click here to read our blog post on how it stops cancer. You can buy it in powder and capsule form.  This episode is a fascinating one, make sure to bring your notepad!

Featuring a slide presentation and related discussion from Dr Seth Wander, including the following topics: Biological impact of clinically relevant biomarkers (eg, ESR1 mutations, PIK3CA/AKT1/PTEN alterations) (0:00) Methodologies for biomarker assessment in clinical practice: Tissue versus liquid biopsy (5:21) Methodologies for biomarker assessment in clinical practice: Novel platforms (13:56) Appropriate timing for assessment of ESR1 and PI3K pathway alterations (17:34) Evolving guidelines for routine biomarker evaluation (21:37) Implications of precision oncology clinical trials for future biomarker utility (25:07) Summary, key questions, future directions (33:09) CME information and select publications  

Featuring an interview with Dr Seth Wander, including the following topics: Deciding between liquid and tissue biopsy; role of epigenetics in oncogenic events (0:00) Potential role of thymidine kinase testing in monitoring response to therapy (4:56) Interpretation of next-generation sequencing testing; use of targeted therapy (10:59) Phase III lidERA Breast Cancer trial and its implications for the use of giredestrant (14:19) Interpreting plots from the Guardant360® test; future applications of circulating tumor DNA (19:07) Toxicity surrounding use of agents targeting the PAM signaling pathway; treatment for patients with PAM pathway alterations and ESR1 mutations (25:15) Potential role of artificial intelligence in profiling biomarkers; comparative efficacy of first- and later-line use of CDK inhibitors (30:26) Case: A woman in her mid 60s diagnosed with hormone receptor (HR)-positive, HER2-low metastatic breast cancer experiences disease progression after 5 years despite letrozole/ribociclib and is found to have ESR1 mutations, treated sequentially with elacestrant then trastuzumab deruxtecan (39:10) Case: A woman in her mid 50s who previously received treatment for localized disease develops progressive metastatic HR-positive, HER2-negative, PIK3CA-mutated breast cancer (45:31) Case: A woman in her late 70s with HR-positive, HER2-negative breast cancer who previously received treatment for localized disease is now diagnosed with progressive PTEN-deficient metastatic disease (51:36) Case: A woman in her early 70s with HR-positive, HER2-low metastatic breast cancer and bone metastases initially receives letrozole in combination with abemaciclib, then abemaciclib monotherapy (53:59) CME information and select publications

Dr Seth Wander from Massachusetts General Hospital in Boston discusses the role of biomarker assessment in the management of HR-positive metastatic breast cancer. CME information and select publications here.

What if everything you're doing to stay healthy—your diet, your supplements, your exercise routine—is only part of the story? What if the real question is whether your body is actually absorbing, using, and benefiting at the cellular level? In this powerful solo episode, Dr. Gillian Lockitch invites you to rethink how you measure wellness and healthy aging by introducing a biomarker that is both completely personal and scientifically valid: your antioxidant protection score.Drawing from her background as a physician and specialist medical biochemist, as well as a life-changing personal health scare, Dr. Lockitch explains the invisible but relentless process of oxidative stress—the cellular damage caused by free radicals that accumulates over time and contributes to aging and chronic disease. Through a vivid and emotional story of her sudden diagnosis of myopic macular degeneration, she brings home the reality that aging is not just about time passing, but about what is happening inside your body every single day. This episode goes beyond theory to illuminate the science of antioxidants as your body's essential defense system. You will learn how endogenous antioxidants produced within your cells work in partnership with dietary antioxidants like carotenoids, and why this balance is critical for protecting your brain, eyes, heart, skin, and overall vitality. Dr. Lockitch also explains why nutrient intake alone is not enough—what truly matters is bioavailability, absorption, and delivery to target tissues.Most importantly, this conversation introduces a breakthrough in personalized health: the ability to measure your antioxidant status quickly, non-invasively, and in real time. By tracking carotenoid levels in your skin, with the new Prysm io, you gain a window into your body's internal resilience against oxidative stress. This transforms your approach from guessing and hoping to knowing and acting. If you've ever wondered whether your healthy lifestyle is truly making a difference, this episode will shift your perspective. It is both a call to awareness and a message of empowerment: when you understand what is happening inside your body, you gain the ability to change it—and to take control of how you age, from the inside out.  Episode Timeline: 00:00 – Welcome and introduction  Dr. Gillian introduces the episode and poses the powerful question: do you know your antioxidant score?  01:10 – Why antioxidant protection matters  Explores the gap between healthy habits and measurable protection against oxidative stress.  03:30 – A personal turning point  Dr. Gillian shares her diagnosis of myopic macular degeneration and the urgent treatment that followed.  06:10 – Lessons from the AREDS study  How targeted nutrients support eye health and why prevention is more powerful than treatment.  08:20 – Measuring what matters  Introduction to antioxidant scanning and the surprising results from early testing.  10:30 – Understanding oxidative stress  Clear explanation of free radicals, cellular damage, and environmental contributors.  13:00 – Internal vs dietary antioxidants  How your body's own defense systems work alongside nutrients from food and supplements.  15:10 – The role of carotenoids in healthy aging  How these plant compounds support the eyes, brain, heart, and skin.  17:00 – Introducing the Prysm iO device  How this non-invasive technology measures antioxidant levels in seconds.  18:30 – From guessing to knowing  Why tracking your antioxidant score empowers better aging decisions.  19:30 – Final thoughts and invitation  Call to action to measure, monitor, and take control of your biological aging.  Connect with Dr. Gillian Lockitch Download your Guide to Nature's Colouful Antioxidants Connect with Dr. Gillian Lockitch at askdrgill@gmail.com to request a  zoom call to demo the Prysm io: Email Subject: Prysm Podcast Join the Growing Older Living Younger Facebook Community here  Share the Growing Older Living Younger podcast link for anyone you care about and invite them to subscribe  

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/XYK865. CME/CC/AAPA credit will be available until March 12, 2027.Pathway to Precision in Ovarian Cancer: A Pathology-Informed Guide to Translating Biomarker Testing Results Into Actionable Treatment With ADCs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Daiichi Sankyo, Inc. and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ATW865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 15, 2027.Charting New Territories in Endometrial Cancer Care: Insights for Personalizing Treatment With Biomarker-Informed Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent medical education grants from GSK and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/XYK865. CME/CC/AAPA credit will be available until March 12, 2027.Pathway to Precision in Ovarian Cancer: A Pathology-Informed Guide to Translating Biomarker Testing Results Into Actionable Treatment With ADCs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Daiichi Sankyo, Inc. and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ATW865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 15, 2027.Charting New Territories in Endometrial Cancer Care: Insights for Personalizing Treatment With Biomarker-Informed Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent medical education grants from GSK and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

Advanced practice providers discuss biomarker testing in patients with colorectal cancer. Listen in to learn from Ann Marie Siney, RN, MSN, ANP-BC, and Kathleen Boyle, DScPAS, PA-C, about familial cancer syndromes associated with colorectal cancer and key biomarker testing often used in patients with colorectal cancer, including their thoughts on overcoming key barriers to testing, education of patients and caregivers, and improving equity in the application of biomarker for all patients. Presenters: Ann Marie Siney, RN, MSN, ANP-BC Division of Hematology/Oncology UCLA Health Santa Monica, California Kathleen Boyle, DScPAS, PA-C  Gastrointestinal Cancer Center Dana-Farber Cancer Institute Boston, Massachusetts Link to full program: https://bit.ly/4spkxiC Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

What does the future of medicine actually look like?In this episode we sit down with Dr. Rhet Langley, MD and Co-founder of Thrive Medicine Clinic to talk about the evolution of healthcare, from traditional hospital medicine, to modern data-driven longevity clinics.Dr. Langley shares how his experience in anesthesia, pain medicine, and military service led him to rethink the way medicine approaches health. Instead of waiting for disease, his clinic focuses on biomarkers, metabolic health, and proactive diagnostics to help patients transform their health long before problems arise.We discuss:• Why many physicians themselves struggle with health • The shift from reactive medicine to preventative longevity care • Biomarker-driven diagnostics and metabolic testing • The real business challenges of building a medical practice • VO₂ max, metabolic flexibility, and longevity data • Why lifestyle foundations matter more than “biohacks” • How AI may transform patient care and data management • The importance of mental health and human connection in medicineIf you're interested in longevity, functional medicine, healthcare entrepreneurship, or the future of medicine, this episode is packed with insights.

In this episode of the Oncology Brothers podcast, we were joined by two international experts — Professor Gary Tse, a pathologist from the Chinese University of Hong Kong, and Dr. Carlos Barrios, a medical oncologist from Brazil — to unpack the evolving landscape of HER2 testing in breast cancer. What was once a binary positive or negative classification has now expanded to include HER2-low and HER2-ultra-low, opening the door to new treatment options for the majority of breast cancer patients. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o   Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Key topics discussed included: How HER2 classification has evolved from a binary result to a continuous spectrum including HER2-low and HER2-ultra-low, driven by the efficacy of antibody drug conjugates like T-DXd Pre-analytical challenges in metastatic settings including tumor heterogeneity The role of IHC, ISH, NGS, and liquid biopsy in HER2 assessment, and how each tool fits into clinical practice. The importance of multidisciplinary collaboration between pathologists and oncologists to ensure accurate interpretation and optimal treatment selection. Join us for this expert discussion on one of the most clinically impactful topics in breast oncology today. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology! #HER2, #BreastCancer, #BiomarkerTesting, #PrecisionOncology, #OncologyBrothers

Your erectile function is literally your body's check engine light—and you're probably ignoring it. If you're a man who tracks his HRV, obsesses over his sleep data, and monitors his testosterone but has no idea what's actually happening with his erectile health, this episode will change everything. Learn why declining erectile function isn't just about aging, how it connects to cardiovascular disease and metabolic health, and what optimal erectile fitness actually looks like versus just "good enough for sex." Whether you're in your 30s noticing subtle changes or in your 40s wondering if what you're experiencing is normal, this episode reveals what your body is trying to tell you before standard medical tests catch it. Discover the difference between maintenance and optimization when it comes to sexual performance. Your dick might be trying to save your life—and you're not even paying attention.   Get the FirmTech cock ring at https://myfirmtech.com/ and use code Naked15 to get 15% off your order. (They are not a sponsor- I just KNOW these devices will help you in bed, and in your overall health).  

What does over 18 months of precision medicine actually look like in practice? In this episode of the Optispan Success Story Series, Dr. Matt Kaeberlein sits down with Carlos Pinto, a tech executive and early Optispan client, to trace his longitudinal health journey from metabolic warning signs to measurable, sustained transformation. Carlos shares how a decade of overlooked biomarkers, a post-pandemic health decline, and a single panic attack became the catalyst for a data-driven approach to his own biology. Together, he and Dr. Kaeberlein review real DEXA, lipid, metabolic, and environmental biomarker data, unpacking what moved the needle, what didn't, and why the answer was rarely simple. This conversation is a candid look at what it means to become your own best health advocate, not through quick fixes, but through personalized, longitudinal learning.Timestamps:0:00 – Cold open & highlights0:50 – Welcome & Carlos's background in tech leadership2:15 – How career ambition displaced health in his 20s and 30s3:39 – A panic attack as the turning point: connecting mental and physical health4:24 – A previous medical wellness program: what worked and what was missing6:34 – Arriving at OptiSpan: intention, mindset, and expectations7:15 – Gateway Day: comprehensive baseline testing and initial surprises8:51 – Early metabolic lessons: CGM data, glucose spikes, and dawn effect11:32 – Confronting white coat hypertension with 78 data points13:28 – How stress, sleep, and nutrition interact to drive metabolic dysfunction15:44 – Personal experimentation as methodology: berberine, time-restricted eating, and fish17:09 – Mercury toxicity from fish consumption: a case study in biomarker surveillance18:33 – Stress management protocols: walking, meditation, and measurable outcomes19:49 – Statin introduction: the role of medication as a tool, not a failure20:27 – DEXA results: visceral fat reduction, body fat loss, and lean mass gain24:17 – Lipid profile transformation: ApoB from ~115 to 70, LDL from 160 to 7425:57 – A1C trajectory and the complexity of glucose optimization30:01 – Reframing medication: proactive use vs. reactive disease management31:29 – Mercury biomarker deep dive: from 2.4 to 16 and back to 232:21 – Goals for the future: sustainability, muscle retention, and mental clarity36:30 – Lineage biological age algorithm: from mortality risk of 54 to 5239:27 – Closing reflections: health as a lifelong trajectory, not a program

The surgeon who spent 12 to14 hours a day in the operating room developed diabetes, uncontrolled high blood pressure, and an autoimmune disease that was eating away at his skull and it forced him to confront what medical school never taught him about actually staying healthy. I sat down with Dr. Darshan Shah, board-certified surgeon, founder of Next Health (one of the largest longevity clinic networks in America), and a doctor who had to reverse his own chronic disease to understand the massive gap between Western medicine and the science of health. We explore why surgeons and physicians become some of the sickest people in healthcare, how functional medicine differs from what you learn in medical school, why biomarker testing matters more than your doctor's "you're fine" assessment, and what root cause medicine actually looks like in practice. Dr. Shah also breaks down the AI revolution happening in cardiovascular imaging with Cleerly scans, how his new AI health dashboard reads your bloodwork and medical records to give you proactive guidance, why Yamanaka factors could regenerate damaged nerves in the brain, and what the future of personalized, preventive medicine looks like when you combine AI with real biological data. Reduce your risk of Alzheimer's with my science-backed protocol for women 30+: https://go.neuroathletics.com.au/youtube-sales-page Subscribe to The Neuro Experience for evidence-based conversations at the intersection of brain science, longevity, and performance. _____ TOPICS DISCUSSED 00:00 Intro: The surgeon who developed the diseases he was treating 01:17 From trauma surgeon to longevity doctor: Dr. Shah's journey 04:18 Autoimmune disease, diabetes, and high blood pressure in a surgeon 10:30 Western medicine vs. the science of health 18:45 Why doctors don't learn prevention in medical school 35:20 Next Health clinics and democratizing longevity medicine 52:40 Biomarker testing and why "your labs are normal" is dangerous 01:03:52 AI health dashboard: uploading bloodwork and getting proactive guidance 01:06:45 Cleerly scans and reversing cardiovascular disease with AI imaging 01:10:08 Yamanaka factors, nerve regeneration, and the future of brain health _______ Thank you to our sponsors Function Health: https://www.functionhealth.com/louisanicola Timeline Mitopure: http://timeline.com/NEURO Ka'Chava: https://kachava.com and use code NEURO for 15% off your first order Wayfair: https://www.wayfair.com/ Fenix: https://www.fenixhealthscience.com/ Arey: https://arey.com/ and use code NEURO _______ I'm Louisa Nicola - clinical neurophysiologist - Alzheimer's prevention specialist - founder of Neuro Athletics. My mission is to translate cutting-edge neuroscience into actionable strategies for cognitive longevity, peak performance, and brain disease prevention. If you're committed to optimizing your brain- reducing Alzheimer's risk - and staying mentally sharp for life, you're in the right place. Stay sharp. Stay informed. Join thousands who subscribe to the Neuro Athletics Newsletter → https://bit.ly/3ewI5P0 Instagram: https://www.instagram.com/louisanicola_/ Twitter : https://twitter.com/louisanicola_ Learn more about your ad choices. Visit megaphone.fm/adchoices

Despite major advances in our understanding of the biology of mental health disorders,  there's no blood test or brain scan that will confirm if you have depression, anxiety, PTSD, or any other psychiatric illness.  And yet, the American Psychiatric Association recently announced that it will be including biomarkers for mental conditions in the next edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM), which guides diagnosis and treatment of mental illness. So how close are we to pinpointing the biological markers of mental illness, and what does that mean for diagnosis? It's complicated.  Host Flora Lichtman untangles some of this science with psychiatry researcher John Krystal. Guest: Dr. John Krystal is a professor of psychiatry, neuroscience, and psychology at the Yale School of Medicine. Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.